1、 Interview experts: Ye Guolin, Lei Ruiwen, Chen Gang. The latest data shows that breast cancer has become the largest cancer in the world, and its incidence rate has jumped to the top of malignant tumors. On December 13, 2023, the National Health Insurance Bureau announced the results of the adjustment of the national health insurance list in 2023. A total of 126 drugs were added to the national health insurance drug list, of which Herceptin, the first monoclonal antibody subcutaneous preparation for breast cancer treatment Trastuzumab injection (subcutaneous injection) also entered the new medical insurance list, becoming the first breast cancer subcutaneous preparation to enter the medical insurance. So, how far is breast cancer from us? Herceptin, a new drug for breast cancer? What benefits and changes will subcutaneous preparations bring to both doctors and patients and help HER2 positive breast cancer enter the "slow disease" management when they are included in the medical insurance catalogue? What preventive measures and risk management should women take to prevent and treat breast cancer and manage chronic diseases? Recently, our reporter had in-depth online and offline exchanges and discussions with several clinical therapists on hot topics of breast cancer prevention and treatment. （1） First expert: Ye Guolin 1. Expert position: Director of the Breast Surgery Department of Foshan First People's Hospital 2. Expert introduction of breast surgery, chief physician. He is good at surgery based comprehensive treatment of breast cancer, and has rich experience in breast conserving, armpit conserving surgery, breast endoscopic surgery, modified radical surgery for breast cancer, breast cancer radical surgery, and thoracoscopic extended radical surgery for breast cancer, especially in breast cancer postoperative reconstruction. In addition, he has rich practical experience in the treatment of postoperative complications of breast cancer, complications of chemotherapy and radiotherapy of breast cancer, and upper limb lymphedema, and has a correct and unique comprehensive evaluation and diagnosis and treatment plan for patients with advanced breast cancer. （2） Second expert: Lei Ruiwen 1. Expert position: Director of Head and Neck Breast Surgery Department of Guangdong North People's Hospital 2. Expert introduction: Master of Medicine, Chief Physician. I have gone to Tianjin Cancer Hospital and Hunan Cancer Hospital for further studies, proficient in the diagnosis and treatment of head and neck breast surgery tumor diseases, diligent in learning, skilled in technology, good at summarizing, willing to contribute, and deeply recognized by the masses. He is good at comprehensive treatment of breast cancer (various breast cancer operations, stage I and II breast reconstruction after breast cancer surgery, breast cancer chemotherapy, targeted therapy, endocrine therapy, etc.); Breast plastic surgery (nipple shaping and reconstruction, breast reduction and lifting, breast augmentation), minimally invasive breast surgery, etc; Minimally invasive and open surgical treatment for thyroid and parathyroid diseases; Surgical treatment of head, neck, and limb tumors (tumor enlargement resection and skin flap repair, lymph node dissection). Carry out 3 provincial and municipal level scientific research projects, publish 15 papers in core journals, and carry out 4 new technologies. （3） Third expert: Chen Gang 1. Expert position: Director of the Cancer Treatment Center at Yangjiang People's Hospital 2. Expert introduction: Doctor of Medicine, postdoctoral fellow at Sun Yat sen University, chief physician, and master's supervisor. Director of Cancer Treatment Center, Discipline Leader, High Level Four Class Talents in Yangjiang City, and Leader of Breast Cancer MDT Expert. Graduated from China Medical University in 1994, obtained a doctoral degree in 2008, and engaged in postdoctoral research at Sun Yat sen University in 2010